Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.

Robert F. Kennedy Jr.’s appointment last month to lead the U.S. Department of Health and Human Services immediately sent ...

Scott Gottlieb, who served early on in Trump's first term, is now warning senators about the impact Kennedy could have on ...

Former FDA commissioner Scott Gottlieb came out against president-elect Trump’s choice of Robert F. Kennedy Jr. to lead the ...

Dr. Scott Gottlieb, Trump’s former FDA commissioner, said he has concerns about the president-elect’s pick for health ...

The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

The New York Times reports that many fear a second Trump administration will weaken the National Institutes of Health, divesting from critical research with long-lasting consequences for science, ...

The sluggish federal response to the H5N1 bird flu outbreak could become even more disjointed and ineffective in the second ...

We’re going to start seeing epidemics of diseases that have long been vanquished, and, God forbid, we see polio reemerge in ...

Dr. Scott Gottlieb, the Commissioner of the Food and Drug Administration during Donald Trump’s first administration, has ...

Trump administration pick for Health and Human Services department could cause rise in preventable disease, health expert ...